Cellectis Reports Increased 2025 Net Loss Amid Revenue Growth, Advances Clinical Pipeline, Faces Patent Suit

summarizeSummary

Cellectis reported a higher net loss for 2025 despite revenue growth from collaborations, while advancing its clinical pipeline and facing a new patent infringement lawsuit.

check_boxKey Events

• Increased Net Loss for FY2025

  The company reported a net loss attributable to shareholders of $67.6 million for the fiscal year ended December 31, 2025, a significant increase from a $36.8 million loss in 2024.

• Substantial Revenue Growth

  Revenues increased to $72.9 million in 2025 from $41.5 million in 2024, primarily driven by the AstraZeneca Joint Research and Collaboration Agreement.

• Extended Cash Runway

  Cellectis reported cash and cash equivalents of $61.5 million and fixed-term deposits of $144.8 million as of December 31, 2025, providing a liquidity runway into the second half of 2027.

• Clinical Pipeline Advancement

  Lasme-cel (UCART22) initiated its pivotal Phase 2 clinical trial in Q4 2025, showing positive preliminary Phase 1 data with a 68% overall response rate. Eti-cel (UCART20x22) demonstrated an 88% overall response rate and 63% complete response rate in preliminary Phase 1/2a results.

auto_awesomeAnalysis

Cellectis S.A.'s annual report for fiscal year 2025 reveals a significant increase in net loss to $67.6 million, up from $36.8 million in 2024, despite a substantial rise in revenues to $72.9 million, primarily driven by the AstraZeneca collaboration. The company maintains a solid liquidity position with $206.3 million in cash and deposits, extending its operational runway into the second half of 2027. Key clinical programs are advancing, with lasme-cel (UCART22) entering pivotal Phase 2 trials and eti-cel (UCART20x22) showing promising early results. However, the company is facing a new patent infringement lawsuit from Factor Biosciences, Inc. concerning its core TALEN-based gene editing technology, which introduces a material legal risk. Additionally, the Servier License Agreement for UCART19 V1 was partially terminated following arbitration, though Cellectis will negotiate a direct license with Allogene. The increased net loss and the patent lawsuit are significant concerns, partially offset by strong revenue growth from partnerships and clinical pipeline progress.